LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

Search

Charles River Laboratories International Inc

Slēgts

SektorsVeselības aprūpe

197 1.63

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

196.2

Max

197.86

Galvenie mērījumi

By Trading Economics

Ienākumi

2.9M

56M

Pārdošana

-27M

1B

P/E

Sektora vidējais

592.3

76.798

EPS

2.43

Peļņas marža

5.529

Darbinieki

18,700

EBITDA

-23M

198M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+1.77% upside

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

950M

9.8B

Iepriekšējā atvēršanas cena

195.37

Iepriekšējā slēgšanas cena

197

Ziņu noskaņojums

By Acuity

20%

80%

27 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

Charles River Laboratories International Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 19. dec. 17:29 UTC

Iegādes, apvienošanās, pārņemšana

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- 2nd Update

2025. g. 19. dec. 16:47 UTC

Galvenie tirgus virzītāji

Galectin Shares Fall After FDA Raises Issues With Belapectin Program

2025. g. 19. dec. 16:10 UTC

Iegādes, apvienošanās, pārņemšana

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- Update

2025. g. 21. dec. 23:51 UTC

Tirgus saruna

Oil Rises Amid Growing U.S.-Venezuela Tensions -- Market Talk

2025. g. 21. dec. 23:45 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 21. dec. 23:45 UTC

Tirgus saruna

Nikkei May Rise as Yen Weakens -- Market Talk

2025. g. 21. dec. 23:35 UTC

Tirgus saruna

Gold Edges Higher Amid Geopolitical Tensions -- Market Talk

2025. g. 19. dec. 22:33 UTC

Peļņas

Volkswagen Halts Imports of Its Electric Bus to U.S. Next Year -- WSJ

2025. g. 19. dec. 22:19 UTC

Peļņas

FedEx Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

2025. g. 19. dec. 21:48 UTC

Iegādes, apvienošanās, pārņemšana

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

2025. g. 19. dec. 21:44 UTC

Peļņas

These Stocks Moved the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

2025. g. 19. dec. 21:38 UTC

Peļņas

Get Ready for New Chip Shortages. Micron's Success All But Guarantees It. -- Barrons.com

2025. g. 19. dec. 21:00 UTC

Tirgus saruna

BEA's Trade-Data Catchup Will Continue Into January -- Market Talk

2025. g. 19. dec. 20:23 UTC

Tirgus saruna

Oil Futures End Down Week on Up Note -- Market Talk

2025. g. 19. dec. 20:14 UTC

Tirgus saruna

U.S. Natural Gas Futures Post Daily Gain, Weekly Loss -- Market Talk

2025. g. 19. dec. 18:38 UTC

Tirgus saruna

U.S. Oil Rig Count Falls By 8 to 406 -- Market Talk

2025. g. 19. dec. 18:00 UTC

Tirgus saruna
Peļņas

Nike's Margin Outlook Shows Quarter-to-Quarter Improvement -- Market Talk

2025. g. 19. dec. 17:41 UTC

Peļņas

These Stocks Are Moving the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

2025. g. 19. dec. 17:24 UTC

Tirgus saruna
Peļņas

Nike's North America Business is Bright Spot in Turnaround -- Market Talk

2025. g. 19. dec. 17:20 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Tech, Media & Telecom Roundup: Market Talk

2025. g. 19. dec. 17:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 19. dec. 16:29 UTC

Peļņas

These Stocks Are Moving the Most Today: Oracle, Nike, FedEx, Micron, DJT, Carnival, BioMarin, Lamb Weston, Winnebago, and More -- Barrons.com

2025. g. 19. dec. 16:20 UTC

Iegādes, apvienošanās, pārņemšana

CPKC: Anticipates Submitting Comments to Surface Transportation Board in Accordance With Procedural Schedule

2025. g. 19. dec. 16:19 UTC

Iegādes, apvienošanās, pārņemšana

CPKC: Approval of Union Pacific-Norfolk Southern Merger Isn't Inevitable

2025. g. 19. dec. 16:18 UTC

Iegādes, apvienošanās, pārņemšana

CPKC: Will Be Thoroughly Reviewing Union Pacific-Norfolk Southern Merger Application Over Coming Days

2025. g. 19. dec. 16:16 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 19. dec. 16:16 UTC

Tirgus saruna

U.K. Public Borrowing Data Shows Slow Progress in Reducing Fiscal Deficit -- Market Talk

2025. g. 19. dec. 16:05 UTC

Iegādes, apvienošanās, pārņemšana

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

2025. g. 19. dec. 16:04 UTC

Iegādes, apvienošanās, pārņemšana

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

2025. g. 19. dec. 15:37 UTC

Tirgus saruna

U.S. Labor Market Weakness Could Cause Further Fed Rate Cuts -- Market Talk

Salīdzinājums

Cenas izmaiņa

Charles River Laboratories International Inc Prognoze

Cenas mērķis

By TipRanks

1.77% augšup

Prognoze 12 mēnešiem

Vidējais 200.55 USD  1.77%

Augstākais 225 USD

Zemākais 170 USD

Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Charles River Laboratories International Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

11 ratings

7

Pirkt

4

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

117.16 / 144.77Atbalsts un pretestība

Īstermiņā

Strong Bullish Evidence

Vidējā termiņā

Weak Bullish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

27 / 374 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat